Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor

Documenti analoghi

• The PP242 Mammalian Target of Rapamycin (mTOR) Inhibitor Activates Extracellular Signal-regulated Kinase (ERK) in Multiple Myeloma Cells via a Target of Rapamycin Complex 1 (TORC1)/ Eukaryotic Translation Initiation Factor 4E (eIF-4E)/RAF Pathway and Activation Is a Mechanism of Resistance
  di: Hoang, Bao, et al.
  Pubblicazione: (2012)
• Regulation of D-cyclin translation inhibition in myeloma cells treated with mTOR inhibitors: Rationale for combined treatment with ERK inhibitors and rapamycin
  di: Frost, Patrick, et al.
  Pubblicazione: (2009)
• mTOR pathway activation in multiple myeloma cell lines and primary tumour cells: pomalidomide enhances cytoplasmic-nuclear shuttling of mTOR protein
  di: Guglielmelli, Tommasina, et al.
  Pubblicazione: (2015)
• CYTOTOXIC PROPERTIES OF A DEPTOR-mTOR INHIBITOR IN MULTIPLE MYELOMA CELLS
  di: Shi, Yijiang, et al.
  Pubblicazione: (2016)
• IL-6-induced Enhancement of c-Myc Translation in Multiple Myeloma Cells: CRITICAL ROLE OF CYTOPLASMIC LOCALIZATION OF THE RNA-BINDING PROTEIN hnRNP A1
  di: Shi, Yijiang, et al.
  Pubblicazione: (2011)